

Exploitation Steering Committee

IMMERSE ESC meeting, March 1st 2022



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Recap of ESG tasks



1. Protection of IPR
 - a) Open innovation outputs
 - i. Scientific impact-creating advances
 - ii. Dynamic modeling and predictive algorithms
 - iii. Interoperability specifications
 - b) Proprietary assets: source-code of the DMMH developed by Movisens



WP8 – Recap of ESG tasks




Figure 1



This project has received funding from the European Union’s Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Tasks and deliverables



2. Track IP and adjust the IPR strategy
 - a) Development of a technology transfer package (IP portfolio) Evelyne will work on finding out what this exactly entails, we'll make a start during the GA. She will start a database on Basecamp on what is our IP, and what defines something as being IP
 - b) Creation of transparent conditions for new IP developed based on project findings



WP8 – Tasks and deliverables



3. Advice on the development of exploitation pathways
 - a) Exploit the software components developed by Movisens ~ license them as stand-alone medical product (CE marking)
 - b) Exploit newly developed software included into the TherapyBuilder ~ fee-for-service basis to researchers and clinicians
 - c) Exploit the document templates that will be generated and extended for the lifecycle process during the IMMERSE project

Remark Jörg: TherapyBuilder is not a product on it's own, it's only a usable product when there's something running on top of it (like platform or library), only the products (a whole system like DMMH) built on TherapyBuilder could be CE marked.

Evelyne will work on finding out what the different regulations are for CE marking.

Jörg attended EC IP-Scan, who remarked we need to look at which texts that we are developing should have copyright. (like document templates, input from medX, can we just share that with other people?) Evelyne will discuss with LRD.



WP8 – Dissemination of (open) innovation outputs



How to get access to IMMENSE data?

Step 1: Submit abstract to automated data check-out system

Example at CCP: DROPS

https://redcap.gbiomed.kuleuven.be/redcap_v12.0.8/index.php?pid=241&__record_cache_complete=1

<https://redcap.gbiomed.kuleuven.be/surveys/?s=WDYAFHWK4>

Outstanding questions:

- RedCap system per site or central RedCap?
- Who is responsible for the set up of the data check-out system for IMMENSE?
- Where will we provide a link to the data check-out system (e.g.: public website)?

There is no such system yet for IMMENSE, Thomas will have a look and see how this can be done at Erlangen. It's a separate RedCap project than where the data is. Evelyne will meet with Thomas about this. Link to data checkout system will be on public website, but first we will allow people within the consortium to have access (so public link will come later).



WP8 – Dissemination of (open) innovation outputs



How to get access to IMMERSE data?

Step 2: Review and approval/decline of abstract within DGB (= SC)



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Dissemination of (open) innovation outputs



How to get access to IMMERSE data?

Step 3: Variable request with time-stamped datafile after preregistration on the OSF website. Statistical analysis is mandatory!

<https://osf.io/dashboard>

Outstanding questions:

- Is there a project in place already for the OSF website? -no, Evelyne will work on this
- Are there guidelines in place on what template to use for the preregistration, for the code, etc. – Evelyne will work on this



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Dissemination of (open) innovation outputs



How to get access to IMMERSE data?

Step 4: Abstract is added to the publication tracker, which is part of the dissemination tracker.

Dissemination

Outstanding questions:

- Who is responsible for updating the dissemination tracker? -Martine, based on SC meetings
- Cfr.: Note Basecamp.



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Dissemination of (open) innovation outputs



How to get access to IMMERSE data?

Step 5: Monitoring of progress/suggest adjustments.



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Dissemination of (open) innovation outputs



How to submit an IMMERSE article (including a registered report?)

Step 1: Basic check of the proposed dissemination. Are the dissemination procedures followed? Is the content in line with the abstract? Check of authorships and acknowledgements.

Step 2: Manuscript is submitted to all relevant partners: 15 **working** days to raise an objection.

Outstanding question: work days?

Step 3: In case of (justified) objection: discuss how to overcome the objection.



WP8 – Dissemination of (open) innovation outputs



What to do after an IMMERSE article has been internally approved?

Send an electronic copy of the published version or final manuscript to the PMO within 6 weeks of publication so it can be added to the dissemination tracking system.

Outstanding questions:

- Should publications be preprinted and if so, at which preprint servers? **Yes, exceptions possible, choice of servers is up to researcher**
- When should we send the manuscript to the PMO (after preprint, after publication, both?) **both**



WP8 – Dissemination of (open) innovation outputs



What are the requirements in terms of open access?

Green open access: Access is granted after an embargo period (maximum 6 months)

Gold open access: Paid open access

Per site: OA budget of approximately 4.000-6.000 euros for OA publications.

Outstanding questions:

- Who decides which journal to publish in?

If there is a KUL researcher as an author on a paper, this paper gets automatically added to the KUL (Lirias) database (=green). EC also has possibilities to publish OA for free there (no impact factor)

Each site has budget available for OA publishing, amount depending in number of researchers there.

OA will be on agenda for GA.

Paid OA should only be used for main papers of IMMERSE.



WP8 – Dissemination of (open) innovation outputs



What are the principles of authorships?

<https://preview.3.basecamp.com/3635894/buckets/10764202/uploads/4453232025/versions/6941557240/representations/eyJfcmlfcmFpbHMlOnsibWVzc2FnZSI6IkJBaDdDRG9RWVhWMGlxOXZjbWxsYm5SVU9ndHlaWE5wZW1WSklnOHINREF3ZURFeU1EQStCam9HUIZRNkNuTjBjbWx3VkE9PSIsImV4cCI6bnVsbCwicHwVyljoidmFyaWF0aW9uIn19--eb997e842f296ea211319855c3766886698ae4df>



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Dissemination of (open) innovation outputs



Dissemination strategies

Outstanding questions:

- Who is responsible for coordinating and monitoring the dissemination activities (WP8 lead?)? **Yes, WP8**
- How will we start setting up and extending our existing networks to reach our stakeholders and know the right channels to disseminate the right type of information? **Evelyne will reach out to IMMERSE partners / WP leads to collect this info**

2.2.4 To maximise scientific impact

- **Scientific community** in the domains of mental health research, psychiatry research, implementation scientists, big data modeling community, health economists and academics active in **the participatory science movement**

Key messages: Scientists will be able to use and valorise novel predictive machine learning algorithms quantifying mental health and disease, improve their understanding of real-life patterns of symptoms and behaviour, implementation science procedures, clinical effectiveness assessments and economic valuation of digital mental health tools stemming from IMMERSE.

Deliverables: **D4.3** Software for identification, visualization and feedback of **behavioural contingencies (M48)**/ **D5.1** report on technology context and self-tracking practices (M18)/ **D5.2** report on user experience during deployment (M48)/ **D7.5** Report on the implementation processes (M48)/ **D7.6** Report on the economic evaluation

Dissemination activities: Scientific publications/ Presentations at scientific symposia and conferences/ Podcasts and blog posts/ Press releases

Channels: Project website/ Peer-reviewed journals/ Scientific symposia and workshops / Social media/News media



WP8 – Dissemination of (open) innovation outputs



Overall outstanding questions:

- How will we ensure that everyone in the project knows the dissemination policy? (e.g.: tutorial, workshops, GA meetings, ...) [GA Friday](#)
- What about the dissemination policy for conference proceedings, blogposts, other material?
- How and when do we decide on topics of interest for the Early Career Researchers?
- More information on GitHub? [Evelyne will meet with Thomas about this. This is for example code for paper analyses.](#)
- More information on the FHIR implementation guide to the HL7 community? [Thomas is now working on D3.2, which is about this.](#)



WP8 – IP portfolio



To do: set up a meeting with an IP officer at LRD to discuss IP rights

Outstanding questions (for the IP officer):

- What are transparent conditions for new IP developed based on project findings? In other words: what is the definition of IP within the project?
- Are all the IP rights already defined or should an additional agreement between all partners be made?



This project has received funding from the European Union's Horizon 2020 research and innovation Programme under grant agreement 945263 (IMMERSE)

WP8 – Exploitation pathways



Discussed in last meeting:

- Summarize per collaborating country what the regulations are in terms of reimbursement for the app.
- Contact Clinical Trial Center (CTC) UZ Leuven Belgium, as well as medX Belgium to ensure that the trial falls under a so-called “clinical evaluation route” (preclinical or “other” clinical investigation), while complying to MDR regulations.

Outstanding questions (to WP7):

- Was there contact with the CTC and with medX already?

With medX it's already set up as an 'other clinical investigation', which may mean that this is enough for the European level, but this needs to be found out. Local ethics committees may not be completely up to date to these regulations as they're very new. Evelyne will check with Simge on current state.

- What about the registration of the trial in the other countries?

